These outcomes suggest that gp96 could potentially be involved in diminishing the efficacy of anti-myeloma therapies, meanwhile, gp96 knockdown augmented myeloma cells’ response to those agents (Usmani et al., 2010). This evidence concerns the gene HSP90B1 and plasma cell myeloma.